SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is actively trending following Saudi FDA approval for its Anktiva treatment in lung cancer, sparking widespread community discussion about its potential as a game-changing, chemotherapy-free cancer therapy and its global expansion. This news, amplified by public statements from Dr. Patrick Soon-Shiong, is driving intense speculation regarding a short squeeze amidst high market interest.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending due to renewed geopolitical uncertainty as Trump's tariff threats over Greenland escalate US-EU tensions, causing futures to dip. The community is sharply divided, with bears anticipating a significant market correction, while bulls expect a "buy the dip" scenario, recalling previous tariff-related downturns that quickly reversed.

Oasis is a layer-one blockchain built to support confidential applications at scale. It’s home to Sapphire, the world’s first private EVM network, Oasis Privacy Layer, a cross-chain privacy solution for any EVM dApp, and Runtime Offchain Logic, a framework that brings trustworthy off-chain computing, onchain. Powered by its ROSE token, Oasis leverages a unique layered architecture and native rollup support, making it ideal for use cases in AI, DeFi, DAOs, gaming, and more.

Oasis Network

Oasis Network (ROSE) is trending due to its pivotal role in privacy-preserving AI and Web3 infrastructure, notably through its Sapphire runtime which secures AI agents and decentralized applications. The community is actively discussing its strong utility and recent collaborations, with many seeing ROSE as an undervalued asset poised for significant growth in the burgeoning privacy and AI sectors.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

Applovin is experiencing heightened volatility due to a fresh short report alleging questionable business practices and broader weakness in the ad tech sector. The community is actively debating if recent price movements are fueled by market manipulation and short-selling pressure ahead of anticipated strong earnings. Many bullish investors are emphasizing the company's AI-driven growth, expanding market reach, and recent analyst upgrades, viewing current price levels as a potential buying opportunity.

Alchemy Pay

Alchemy Pay is trending due to significant developments, including its upcoming Level 1 Alchemy Chain and numerous new partnerships and Money Transmitter Licenses expanding its global fiat-crypto on-ramp services. The community is vigorously debating its potential as a payment infrastructure solution, with strong bullish sentiment driven by its enhanced utility and tokenomics.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is currently trending due to buzz around a massive US government contract for its Foundry Services and increasing speculation that Apple could become a key manufacturing client. This news, coupled with recent analyst upgrades, has bulls anticipating a significant rally post-earnings, while skeptics point to potential price manipulation and a stretched valuation. The stock's performance is seen as a barometer for the future of domestic chip manufacturing and its role in the booming AI sector.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending due to significant insider confidence, highlighted by a director's recent share purchase, and the official groundbreaking of its $100 billion U.S. megafab. The community is actively discussing an unprecedented and sustained shortage in memory chips, especially for AI, driving strong bullish sentiment around the company's strategic expansions and HBM products. Investors are anticipating continued growth as Micron addresses escalating demand.

BlackRock Institutional Trust Company N.A. - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is trending amid anticipation of a Supreme Court ruling on tariffs, which could influence inflation and trade stability, alongside ongoing discussions regarding political pressure on the Federal Reserve's independence. This has created a divided community, with some viewing long-term bonds as a potential recession hedge, while others remain bearish due to persistent yield concerns and broader economic uncertainty.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

KENDU is trending with strong community conviction, driven by its unique model as a "permissionless brand" actively building real-world products and businesses. The bullish community celebrates its relentless "IRL" efforts, including launching Kendu Spice on Amazon and developing Kendu Energy drinks and entertainment initiatives. Available across Ethereum, Solana, and Base, KENDU is seen as a long-term play with dedicated holders who believe it's establishing a new paradigm for decentralized branding.

Global X Funds - Global X DAX Germany ETF

Global X DAX Germany ETF

The Global X DAX Germany ETF is actively discussed amid ongoing US-Europe trade tensions, particularly surrounding escalating tariff threats and Europe's planned fiscal stimulus for defense and infrastructure. Community sentiment remains largely bullish, focusing on Elliott Wave technical setups that suggest continued upside potential, despite recent volatility and broader economic concerns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>H.C. Wainwright raised MoonLake’s price target to $32 from $26 and maintained a ‘Buy’ rating.</li><li>BTIG said the FDA approval ‘clears a significant overhang’ for MoonLake’s clinical program.</li><li>MoonLake plans to submit its biologics license application in the second half of 2026.</li></ul>MoonLake Immunotherapeutics (MLTX) remained on investors’ radar after its shares rose 5% in premarket trading on Friday, following favorable brokerage action tied to positive feedback from the U.S. Food and Drug Administration (FDA) on its treatment for hidradenitis suppurativa, a chronic inflammatory skin condition.<a href="https://stocktwits.com/symbol/MLTX">MLTX</a> was among the top trending tickers on Stocktwits at the time of writing.BTIG upgraded MoonLake Immunotherapeutics to ‘Buy’ from ‘Neutral’ and set a $24 price target, citing a recent regulatory update, according to TheFly.<h2 class="st-heading-2">The FDA Feedback</h2>The FDA <a href="https://stocktwits.com/news-articles/markets/equity/why-did-mltx-stock-jump-45-in-pre-market-today/cmUbJFWR4Pt">confirmed</a> that MoonLake can establish the effectiveness of Sonelokimab (SLK) in hidradenitis suppurativa without additional trials, a development BTIG believes clears a significant overhang for the company’s clinical program and could position SLK for FDA approval.This would be supported by existing data from the VELA-1, VELA-2, and MIRA studies. The company plans to submit its biologics license application in the second half of 2026.H.C. Wainwright raised MoonLake’s price target to $32 from $26 and maintained a ‘Buy’ rating. The company’s FDA meeting outcome delineates a path to registration, the firm said.The stock closed 27% higher on Thursday following the FDA feedback.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits remained in the ‘extremely bullish’ zone over the past 24 hours, accompanied by ‘extremely high’ message volumes.<img src="https://news.stocktwits-cdn.com/MLTX_jpg_6f56883898.webp" alt="MLTX.jpg">One user sees potential conversations regarding mergers and acquisitions following the FDA feedback.<stembedurl>https://stocktwits.com/Atdanaiw/message/641311151</stembedurl>Another user believes MLTX’s value needs to grow further before a probable acquisition.<stembedurl>https://stocktwits.com/Newcar/message/641308484</stembedurl>MoonLake had reportedly turned down a $3 billion acquisition offer from Merck (MRK) in June last year.The stock has been under heavy selling pressure over the past year, declining more than 70%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/glue-stock-slips-pre-market-after-pricing-300-million-public-offer-at-discount/cmU2ghYR4dQ">GLUE Stock Slips Pre-Market After Pricing $300 Million Public Offer At Discount</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

In this photo illustration, the MoonLake Immunotherapeutics (Moon Lake) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

MLTX Stock Extends Rally As FDA Feedback Spurs Bullish Brokerage Action – Retail Speculates On Potential M&A Conversations

BTIG upgraded MoonLake Immunotherapeutics to ‘Buy’ from ‘Neutral’ after the FDA said the company could show the effectiveness of Sonelokimab without additional HS trials.

Equity

<ul class="summary-bullets"><li>The FDA feedback indicates the company can establish&nbsp;substantial evidence of effectiveness without conducting additional&nbsp;hidradenitis suppurativa trials.</li><li>The firm remains on track to submit its Biologic License Application for Sonelokimab in the second half of 2026.</li><li>MoonLake will host an Investor Day on February 23 to review FDA feedback from the Type B meeting.</li></ul>Shares of MoonLake Immunotherapeutics (MLTX) surged 45% in premarket trading on Thursday after the company said it received positive regulatory feedback from the U.S. Food and Drug Administration (FDA) following a Type B meeting regarding Sonelokimab (SLK), a drug used to treat hidradenitis suppurativa (HS), a chronic inflammatory skin disorder.The FDA feedback indicates the company can establish substantial evidence of effectiveness (SEE) without conducting additional HS trials, using a Biologic License Application (BLA) supported by data from its existing VELA-1, VELA-2, and MIRA studies.The agency advised including MIRA results to support efficacy and submitting VELA-2 data to inform the safety profile. Based on the official meeting outcome, the company remains on track to submit its BLA for Sonelokimab in the second half of 2026.“The positive outcome of our Type B meeting with the FDA provides the clarity needed to support a pathway to approval for our existing HS program, with no additional clinical trials required. In addition, the fact that we can prepare the BLA with the wealth of data across the VELA and MIRA trials provides us and the FDA with flexibility to determine the best label possible, so that SLK, if approved, can have the most positive impact for HS patients,” said Jorge Santos da Silva, Founder and Chief Executive Officer at MoonLake Immunotherapeutics.<h2 class="st-heading-2">2026 Pipeline</h2>MoonLake will host an Investor Day on Feb. 23, 2026, to review the FDA feedback from the Type B meeting and share new clinical data for SLK across indications, along with updates to its 2026 catalyst outlook.The company also expects a steady flow of clinical readouts over the next year, including Phase 2 data in axial spondyloarthritis and multiple Phase 3 updates in psoriatic arthritis and HS. Key milestones include a Phase 2 axSpA readout in Q1 2026, several Phase 3 readouts by mid-2026, and a planned BLA submission in the second half of 2026.<h2 class="st-heading-2">How Did Stockwits Users React?</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, amid ‘high’ message volumes. <a href="https://stocktwits.com/symbol/MLTX">MLTX</a> was among the top trending stocks on the platform at the time of writing.<figure class="image"><img src="https://news.stocktwits-cdn.com/MLTX_jpg_70c33bd6fe.webp" alt="MLTX.jpg" width="916" height="96"><figcaption>MLTX's Sentiment Meter and Message Volumes at Premarket on Jan. 8, 2026 | Source: Stocktwits</figcaption></figure>One user expects the stock to climb to $22 within a few sessions. It is currently trading at $16.2.<stembedurl>https://stocktwits.com/discountcroesus1/message/641193716</stembedurl>The stock has been under heavy selling pressure over the past year, declining nearly 80%.Read Also: <a href="https://stocktwits.com/news-articles/markets/equity/why-vnda-stock-falling-premarket/cmUbEA9R4Pn">Vanda Stock Drops 10% Premarket After FDA Rejects Jet Lag Drug Application</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a MoonLake Immunotherapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Why Did MLTX Stock Jump 45% In Pre-Market Today?

The company said it received positive regulatory feedback from the U.S. FDA following a Type B meeting regarding a drug used to treat hidradenitis suppurativa, a chronic inflammatory skin disorder.

Can ETF Winners of Q4 of 2025 Rally in Q1 of 2026?

Q4's top ETF winners -- silver, biotech and lithium -- outpaced markets. Can SIVR, SLV, BBC and LITP extend gains into 2026?

<ul class="summary-bullets"><li>H.C. Wainwright conservatively expects approval by the middle of 2026 and sees the shares trading well into the year-end.</li><li>Capricor’s bumper rally on Wednesday helped the stock turn green for the year.</li><li>Retail sees the stock as a long-term winner following the Phase 3 results.</li></ul>Two decades after its modest beginnings and more than a decade after becoming a public company, San Diego, California-based Capricor Therapeutics made another stride toward becoming a commercial-stage company. After a failed first try, the small-cap biotech is hoping to push its experimental cell-therapy for a rare genetic muscular disorder past the finish line without any hiccups.Wall Street analysts and the investment community received the recently released late-stage trial data for the treatment candidate well. While sell-side analysts were generous with their price target hikes, signaling their excitement toward the data, investors sent the stock up by over 530% at one point in Wednesday’s session. The initial euphoria faded slightly, but didn’t die out, as<a href="https://stocktwits.com/symbol/CAPR">&nbsp;Capricor’s stock</a> had enough verve to finish the day up 371% at $29.96,&nbsp;ending at an eight-year high and marking its best day ever.<img src="https://news.stocktwits-cdn.com/Screenshot_2025_12_04_at_2_28_48_AM_png_599beb080a.webp" alt="Screenshot 2025-12-04 at 2.28.48 AM.png">Source: Koyfin<h2 class="st-heading-2">What Fueled CAPR’s Stratospheric Rally</h2>Wednesday, before the market opened, Capricor reported positive topline results from the Phase 3 study, dubbed HOPE-3, evaluating its Duchenne Muscular Dystrophy (DMD) cell therapy candidate, Deramiocel.-The primary endpoint, measured as the performance of upper limb (PUL), was met — showing statistically and clinically meaningful treatment effects in 54% of the patients.-The key secondary endpoint of “Left Ventricular Ejection Fraction (LVEF),” a measure of heart health, was also met.&nbsp;Thus, Deramiocel was shown to produce significant skeletal and cardiac benefits, supporting its credentials as a potential “first-in-class therapy” for Duchenne cardiomyopathy, the leading cause of mortality in DMD. The trial also gave the cell therapy a clean chit for its safety and tolerability.Capricor said it would submit the detailed results from the HOPE-3 study at a future scientific meeting and for publication in a peer-reviewed journal.Earlier in July, the FDA shot down Capricor’s initial application for Deramiocel, issuing a complete response letter (CRL) — a notice that an application cannot be approved in its current form. The agency expressed wariness about the company's efficacy data at the time and sought additional data. Industry experts saw it as a signal that the new leadership at the FDA could be veering toward a cautious approach.&nbsp;&nbsp;CEO Linda Marbán said the study results, in addition to the evidence from the HOPE-2 and HOPE-2 OLE studies, would address the clinical issues in the CRL and support regulatory approval.DMD is caused by a mutation in the DMD gene that prevents the body from producing the protein dystrophin. A lack of dystrophin hits muscle fibres, leading to muscle damage and loss.&nbsp;<h2 class="st-heading-2">What’s At Stake For Capricor</h2>According to Grand View Research, the DMD drugs<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.grandviewresearch.com/industry-analysis/duchenne-muscular-dystrophy-dmd-drugs-market">&nbsp;market</a> is expected to grow at a compounded annual growth rate (CAGR) of 16.8% from 2024, reaching $9.91 billion in 2030. North America’s revenue share was at 45% in 2023. Global Data, meanwhile, has a more muted forecast, predicting a $5.2 billion market opportunity in 2033.&nbsp;<img src="https://news.stocktwits-cdn.com/Screenshot_2025_12_04_at_3_25_08_AM_png_f4173223fa.webp" alt="Screenshot 2025-12-04 at 3.25.08 AM.png">Source: Grandview ResearchThe DMD market is currently led by Sarepta, which has a gene-replacement therapy called Eteplirsen. Elevidys, a one-time single-dose gene transfer therapy, was approved in June 2023, and its label was expanded a year later to include patients ages four and older. The gene therapy generated $131.5 million in revenue for Sarepta in the third quarter.Capricor’s Deramiocel differs from Elevidys in that it is a cell therapy that administers the patient's cardiosphere-derived cells, which secrete exosomes. The latter uses a manufactured gene for delivering the micro-dysrophin gene.Sarepta also has three FDA-approved exon-skipping therapies, Exondys 51, Amondys 45 and Vyondys 53, and it is also currently working on RNA therapies.<h2 class="st-heading-2">Big Price Target Bumps</h2>Following the data, H.C. Wainwright upped the price target for Capricor's stock to $60 from $24 and kept a 'Buy' rating, the Fly reported. The firm called the data a "decisive" win. With 78% of participants having underlying cardiomyopathy, the trial results addressed FDA concerns about sample size, the firm said. It conservatively expects approval by the middle of 2026 and sees the shares trading well into the year-end.Alliance Global called the data "unequivocally and wholly positive" and removed the speculative tag from the stock. The firm hiked its price target for the stock to $48 from $16.<h2 class="st-heading-2">Retail Convinced Of Capricor Opportunity</h2>On Stocktwits, retail investors held an 'extremely bullish' stance on Capricor stock as of early Thursday. The message volume on the stream was 'extremely high as well.A majority of retail traders are sold on Capricor's long-term potential. An ongoing Stocktwits poll asking users "What's your move on $CAPR after this Phase 3 win?" found that 53% of respondents said "This is legit — CAPR becomes a long-term winner," while 18% remained on the sidelines, waiting for approval to come through. About 29% shrugged off the rally as an "overreaction."<a href="https://stocktwits.com/StocktwitsPolls/message/638043423"><img src="https://news.stocktwits-cdn.com/CAPR_Stocktwits_poll_png_bc7624531b.webp" alt="CAPR Stocktwits poll.png"></a>CAPR stock has&nbsp;soared about 117% this year, as Wednesday's bumper rally helped it recoup all its losses to that point and turn green for the year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:<a href="https://stocktwits.com/news-articles/markets/equity/core-weave-vs-nebius-ai-infra-s-breakout-duo-backed-by-nvidia-is-outrunning-big-tech/cLIXYiKRE12">&nbsp;</a><a href="https://stocktwits.com/news-articles/markets/equity/whispers-of-an-apple-deal-rebooted-intel-s-year/cLIXAvERE1L">Whispers Of An Apple Deal Rebooted Intel’s Year — Now The Market’s Asking Whether The Old Chip Giant Can Rise Again</a>

In this photo illustration, the lCapricor Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Capricor’s Red-Hot Rally Has Wall Street And Retail Hooked — And Fresh DMD Data Could Keep Fueling The Fire

 DMD patients may soon gain access to a therapy that not only targets muscle decline but also tackles heart complications — the leading cause of death in this rare genetic disorder.

Biotech ETFs Hovering Around a 52-Week: Here's Why 

Biotech is back! Regulatory tailwinds, cheaper valuations, and Fed cut hopes are boosting ETFs like XBI and IBB. Is the rebound just starting?

Biotech ETFs Bounce Back in 2025: Here's Why  

Biotech ETFs rally. IBB, ARKG, SBIO, BBC, CANC and BBP soar as Fed rate cut optimism, FDA approvals, deals and cheaper valuations drive the space in 2025.

Shares of Compass Pathways Plc. (CMPS) slumped 47% on Monday afternoon after the <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.compasspathways.com/News--Events-/news/news-details/2025/Compass-Pathways-Successfully-Achieves-Primary-Endpoint-in-First-Phase-3-Trial-Evaluating-COMP360-Psilocybin-for-Treatment-Resistant-Depression/default.aspx">results</a> from the late-stage trials of COMP360 in treatment-resistant depression fell short of market expectations.COMP360 is a synthetic, proprietary formulation of psilocybin. Psilocybin is part of a group of drugs called psychedelics or hallucinogens with the ability to alter one’s sense of perception.Compass Pathways said that a single dose of the drug reduced symptom severity by 3.6 points from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) as compared to placebo at week 6.The company said it will discuss the “highly statistically significant and clinically meaningful” data with the U.S. Food and Drug Administration, which has yet to review it.The company is also running another late-stage trial for the drug, which aims to evaluate the efficacy of two fixed doses taken three weeks apart.According to Compass Pathways, an estimated 21 million adults in the U.S. suffer from major depression, and approximately 9 million are drug-treated.Approximately a third of patients with major depressive disorder will develop treatment-resistant depression, which is defined as an inadequate response to two or more appropriate courses of approved medications.Following the announcement, Evercore ISI downgraded Compass Pathways to ‘In Line’ from ‘Outperform’ with a price target of $6, down from $11.The reduction in symptom severity by 3.6 points as compared to placebo on a standardized depression scale "underwhelmed," the analyst told investors, as per TheFly.This dataset does indicate Compass may have an approvable drug, but the firm noted that durability is a key component for commercial success, and this will remain a question with relatively unclear durability in a mid-stage trial and a weaker effect at 6 weeks in the late-stage trial.H.C. Wainright, however, is more optimistic and noted that the results from the late-stage study mark "a historic first for a psychedelic therapy." The data also positions COMP360 as "a potential first-in-class treatment in a large, underserved depression market," said the analyst, who reiterated a ‘Buy’ rating and $45 price target on the shares.On Stocktwits, retail sentiment around CMPS jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:631/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_23_at_12_27_47_PM_png_d7e1356560.webp" alt="CMPS's Sentiment Meter and Message Volume as of 12:25 p.m. ET on June 23, 2025 | Source: Stocktwits" width="631" height="60"><figcaption>CMPS's Sentiment Meter and Message Volume as of 12:25 p.m. ET on June 23, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that while the late-stage results were good, the market wants ‘groundbreaking’ results.<stembedurl>https://stocktwits.com/aaronmag13/message/618680560</stembedurl><a href="https://stocktwits.com/symbol/CMPS">CMPS stock</a> is down by about 35% this year and nearly 61% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/rezolve-ai-to-be-added-to-russell-indices-after-revenue-surge/chm57C7RRdR">Rezolve Ai To Be Added To Russell Indices After Revenue Surge: Retail Echoes Confidence</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Compass Pathways Stock Slumps After Positive Late-Stage Trial Results From Psychedelic Drug ‘Underwhelm’ Analysts

The company said it will discuss the “highly statistically significant and clinically meaningful” data with the U.S. Food and Drug Administration, which has yet to review it.

Nasdaq-listed shares of Autolus Therapeutics PLC (AUTL) were in the spotlight on Friday after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://autolus.gcs-web.com/news-releases/news-release-details/autolus-therapeutics-announces-positive-chmp-opinion">announced</a> that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) approve its Obe-cel therapy for the treatment of a particular type of blood cancer.Obe-cel is short for Obecabtagene Autoleucel. The CHMP has recommended that the European Commission approve it for the treatment of adult patients over the age of 26 with relapsed or refractory B-cell precursor acute Lymphoblastic Leukemia, an aggressive type of blood cancer that can also involve the lymph nodes, spleen, liver, central nervous system, and other organs.According to Autolus, there are about 6,000 new cases of acute Lymphoblastic Leukemia diagnosed every year in Europe.The committee’s recommendation was based on the results of the company’s open-label, multiple-centre study and will serve as the basis for the commission’s final decision on Autolus’ marketing authorization application.The European Commission's decision will apply to all 27 European Union Member States, Iceland, Norway, and Liechtenstein.Obe-cel received approval from the U.S. Food and Drug Administration in November 2024 and conditional marketing authorization from the U.K.’s Medicines and Healthcare Products Regulatory Agency in April.On Stocktwits, retail sentiment around AUTL improved from ‘bearish’ to ‘neutral’ territory over the past 24 hours while message volume remained at ‘neutral’ levels.<figure class="image"><img style="aspect-ratio:627/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_23_at_12_01_00_PM_png_a607fcc3b0.webp" alt="AUTL's Sentiment Meter and Message Volume as of 12:00 p.m. ET on May 23, 2025 | Source: Stocktwits" width="627" height="64"><figcaption>AUTL's Sentiment Meter and Message Volume as of 12:00 p.m. ET on May 23, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user expressed optimism about the therapy receiving approval in the EU.<stembedurl>https://stocktwits.com/Mancunian/message/615691105</stembedurl><a href="https://stocktwits.com/symbol/AUTL">AUTL stock</a> is down by about 42% this year and 61% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/amazon-backed-anthropic-claude-blackmails-engineer/ch0QVgWRbqH">Amazon-Backed Anthropic's AI Model Reportedly Blackmails Engineer Having An Affair To Avoid Being Shut Down In Test Run</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Autolus Therapeutics Gets Favorable Recommendation For Approval Of Cancer Therapy In EU: Retail Sentiment Brightens

CHMP has recommended that the European Commission approve the therapy for treating adult patients over the age of 26 with relapsed or refractory B-cell precursor acute Lymphoblastic Leukemia. 

Shares of biotech Galapagos NV (GLPG) dipped nearly 1% in pre-market trade on Tuesday after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.glpg.com/press-releases/galapagos-announces-departure-of-thad-huston-cfo-and-coo-as-of-august-1-2025/">announced</a> the departure of its CFO and COO, Thad Huston, effective August 1, 2025.The company said Huston has decided to leave and return to the U.S. for personal and professional reasons. It added that it expects to announce a new CFO “in the coming months,” but did not share a definitive timeline.Huston joined Galapagos in July 2023 from Kite Pharma, Inc. Before that, he worked for over 25 years at Johnson &amp; Johnson.CEO Paul Stoffels said that Huston will stay in his role until Aug. 1 to “ensure a smooth handover of responsibilities.”Galapagos, which has operations in Europe and the U.S., reported its full-year 2024 financial results earlier this year. The company logged a 15% jump in total net revenue to €275.6 million (about $312 million), while diluted earnings per share fell to $1.12 from $3.21 year-over-year (YoY).As of the end of 2024, it had €3.3 billion in cash and financial investments and said that it intends to separate into two publicly traded companies and establish SpinCo with approximately €2.45 billion in current cash.A shareholder meeting regarding the separation of Galapagos into two publicly traded entities is expected to be convened in mid-2025.On Stocktwits, retail sentiment about Galapagos fell from ‘extremely bullish’ to ‘bullish’ territory over the past 24 hours while message volume remained at ‘high’ levels.<figure class="image"><img style="aspect-ratio:650/148;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_15_at_8_24_57_AM_png_80bd7d6071.webp" alt="GLPG's Sentiment Meter and Message Volume as of 8:25 a.m. ET on April 14, 2025 | Source: Stocktwits" width="650" height="148"><figcaption>GLPG's Sentiment Meter and Message Volume as of 8:25 a.m. ET on April 14, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/GLPG">GLPG stock</a> is down by over 13% year-to-date and by nearly 19% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/johnson-and-johnsons-q1-earnings-beat-estimates/chQRaxWRbaH">Johnson &amp; Johnson’s Q1 Earnings Beat Estimates, 2025 Guidance Revised To Account For Intra-Cellular Therapies Acquisition: Retail’s Positive</a>For updates and corrections, email newsroom[at]stocktwits[dot]com(Exchange Rate: 1 Euro = 1.13 USD)

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Galapagos Announces CFO Exit With No Successor Named Yet: Retail’s Disappointed

The company expects to announce a new CFO “in the coming months.”

MoonLake Immunotherapeutics, a clinical-stage biotech firm valued at $2.6 billion, is generating excitement with its experimental treatment for hidradenitis suppurativa (HS), a chronic and painful skin condition.&nbsp;On Friday, Goldman Sachs upgraded the stock to a&nbsp;'Buy' from&nbsp;'Neutral,' with analyst Richard Law raising the price target from $62 to $82 — an 85% upside from current levels, CNBC&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/2025/01/17/this-little-known-biotech-stock-is-a-buy-thats-primed-to-double-in-price-goldman-says.html">reported</a>.While MoonLake is gaining traction among institutional investors, it remains underfollowed on Stocktwits, with fewer than 600 watchers.&nbsp;Over the past year, retail interest has been budding, with a 12% increase in followers, even as the stock has fallen 26%.Law reportedly believes MoonLake's experimental nanobody treatment, sonelokimab (SLK), holds transformative potential.&nbsp;SLK demonstrated impressive efficacy in phase 2 trials, leading to optimism about its success in phase 3.&nbsp;Additionally, SLK's inclusion of AbbVie's Skyrizi — currently the standard of care for psoriatic arthritis (PsA) — as a reference treatment offers a key differentiator, according to the analyst.Law suggests that while this adds some risk, the potential to position SLK as superior in a competitive market far outweighs the drawbacks.Goldman Sachs isn't alone in its optimism. Oppenheimer included MoonLake among its top biotech picks for 2025, alongside Capricor, Gilead, Kymera, Praxis, and Prothena.&nbsp;The brokerage sees biotech equities as undervalued relative to other sectors, with strong catalysts like lower interest rates, robust M&amp;A prospects, and transformative data releases creating a favorable backdrop this year.MoonLake ended the third quarter (Q3) of 2024 with $493.9 million in cash, cash equivalents, and marketable securities, which the company said provides a runway through 2026.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Over the past year, retail interest has been budding, with a 12% increase in followers, even as the stock has fallen 26%.

Goldman Sachs Thinks Mid-Cap Biotech MoonLake Could Soar Over 80%: Is Retail Watching Closely?

Oppenheimer has included MoonLake among its top biotech picks for 2025, alongside Capricor, Gilead, Kymera, Praxis, and Prothena.

SBIO
ALPS Fund Services - ALPS Medical Breakthroughs ETF

Feed

News

Sentiment

Fundamentals

Info

Latest SBIO News

SBIOALPS Fund Services - ALPS Medical Breakthroughs ETF